We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.13B
AUM Growth
+$1.04B
Cap. Flow
+$940M
Cap. Flow %
44.08%
Top 10 Hldgs %
46.5%
Holding
110
New
45
Increased
37
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$98.6M
2
GILD icon
Gilead Sciences
GILD
+$96.5M
3
PFE icon
Pfizer
PFE
+$46.4M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.9M
5
ABBV icon
AbbVie
ABBV
+$26.7M

Top Sells

Rank Stock Value
1
FRX
FOREST LABORATORIES INC
FRX
+$10.9M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.11M
3
AEGR
Aegerion Pharmaceuticals
AEGR
+$1K

Sector Composition

Rank Sector Weight
1 Healthcare 81.82%
2 Real Estate 2.39%
3 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAY icon
76
Accuray
ARAY
$33.9M
$5.31M 0.25%
731,943
– –
MACK
77
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$4.99M 0.23%
72,166
– –
CNC icon
78
Centene
CNC
$30.1B
$4.96M 0.23%
240,000
– –
ALNY icon
79
Alnylam Pharmaceuticals
ALNY
$27.4B
$4.81M 0.23%
61,595
– –
CLVS
80
DELISTED
Clovis Oncology, Inc.
CLVS
$4.72M 0.22%
104,051
+56,687
+120% +$2.37M
INCY icon
81
CALL
Incyte
INCY
$24.9B
$4.59M 0.22%
+93,500
New +$4.69M
ALXN
82
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.44M 0.21%
+26,800
New +$4.4M
NBIX icon
83
CALL
Neurocrine Biosciences
NBIX
$18.7B
$4.41M 0.21%
+281,600
New +$4.21M
MYGN icon
84
CALL
Myriad Genetics
MYGN
$507M
$4.33M 0.2%
+112,200
New +$4.19M
MYGN icon
85
Myriad Genetics
MYGN
$507M
$4.33M 0.2%
+112,200
New +$4.19M
BLUE
86
CALL
DELISTED
bluebird bio
BLUE
$4.25M 0.2%
+9,140
New +$4.22M
BIIB icon
87
CALL
Biogen
BIIB
$30.7B
$4.23M 0.2%
+12,800
New +$4.22M
IPCI
88
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$4.23M 0.2%
140,400
– –
NPSP
89
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$4.06M 0.19%
+156,000
New +$4.48M
NKTR icon
90
CALL
Nektar Therapeutics
NKTR
$2.41B
$4.04M 0.19%
+22,320
New +$4.27M
NKTR icon
91
Nektar Therapeutics
NKTR
$2.41B
$4.04M 0.19%
+22,320
New +$4.27M
ILMN icon
92
CALL
Illumina
ILMN
$31B
$3.87M 0.18%
+24,261
New +$4.06M
EPZM
93
DELISTED
Epizyme, Inc
EPZM
$3.83M 0.18%
141,262
+71,100
+101% +$2.21M
TEVA icon
94
CALL
Teva Pharmaceuticals
TEVA
$41.2B
$3.69M 0.17%
+68,600
New +$3.63M
KYTH
95
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$3.65M 0.17%
111,433
+62,433
+127% +$2.2M
ALGN icon
96
Align Technology
ALGN
$12.4B
$3.64M 0.17%
+70,400
New +$3.83M
KPTI icon
97
Karyopharm Therapeutics
KPTI
$159M
$3.56M 0.17%
+6,798
New +$3.84M
PTCT icon
98
PTC Therapeutics
PTCT
$6.26B
$3.48M 0.16%
79,150
– –
LGND icon
99
Ligand Pharmaceuticals
LGND
$5.94B
$3.25M 0.15%
+110,928
New +$3.68M
THOR
100
DELISTED
THORATEC CORPORATION
THOR
$3.03M 0.14%
+113,300
New +$3.22M
1 2 3
4
5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Tekla Capital Management held 110 positions worth $2.13B, up 96% from $1.09B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Tekla Capital Management deployed $940M of net new capital in Q3 2014, opening 45 new positions and adding to 37 existing holdings. Its largest new stake was Johnson & Johnson: 327,212 shares worth $34.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.11M trimmed.

  • Tekla Capital Management's largest Q3 2014 buy was Johnson & Johnson: 327,212 shares worth $34.9M.
  • Tekla Capital Management added most to Celgene Corp in Q3 2014, an estimated $98.6M increase.
  • Tekla Capital Management's biggest Q3 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.11M.
  • Tekla Capital Management fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $10.9M.
  • Tekla Capital Management's ten largest holdings make up 47% of its $2.13B portfolio in Q3 2014.
  • Tekla Capital Management opened 45 new positions and closed 2 in Q3 2014.
  • Tekla Capital Management's portfolio value rose 96% quarter-over-quarter to $2.13B.

Based on Tekla Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.